• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.中枢神经系统复发的弥漫性大B细胞淋巴瘤缺乏致癌性MYD88和CD79B突变。
Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.
2
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.CD5阳性弥漫性大B细胞淋巴瘤中的MYD88、CD79B和CARD11基因突变
Cancer. 2017 Apr 1;123(7):1166-1173. doi: 10.1002/cncr.30404. Epub 2016 Dec 4.
3
MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.MYD88、CARD11和CD79B致癌突变在印度初发性淋巴结弥漫性大B细胞淋巴瘤队列中是罕见事件。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):311-318. doi: 10.1097/PAI.0000000000000585.
4
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.原发性睾丸弥漫性大B细胞淋巴瘤中致癌性MYD88和CD79B突变的高发生率。
Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20.
5
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.原发性中枢神经系统弥漫性大B细胞淋巴瘤中致癌性MYD88和CD79B突变的发生率显著较高。
Leuk Lymphoma. 2015 Jul;56(7):2141-5. doi: 10.3109/10428194.2014.979413. Epub 2015 Jan 14.
6
Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.原发肾上腺弥漫性大 B 细胞淋巴瘤的形态学模式及与 MYD88 L265P、CD79B 突变的相关性。
Am J Surg Pathol. 2020 Apr;44(4):444-455. doi: 10.1097/PAS.0000000000001386.
7
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant and wildtype .依鲁替尼与化疗联合应用使携带突变型和野生型的多次复发腿部型弥漫性大B细胞淋巴瘤患者获得持久缓解。
Haematologica. 2017 Jul;102(7):e275-e277. doi: 10.3324/haematol.2016.161893. Epub 2017 Mar 24.
8
High prevalence of and mutations in intravascular large B-cell lymphoma.血管内大B细胞淋巴瘤中 和 突变的高发生率。 （你提供的原文中有缺失内容，我按照完整格式翻译了）
Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7.
9
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88 /CD79B diffuse large B-cell lymphoma.一项单中心、真实世界研究，评估 BTK 抑制剂在 MYD88/CD79B 弥漫性大 B 细胞淋巴瘤初始治疗中的疗效。
Cancer Med. 2024 Feb;13(4):e7005. doi: 10.1002/cam4.7005.
10
[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].泽布替尼与利妥昔单抗联合治疗伴CD79B和MYD88突变的原发性皮肤弥漫性大B细胞淋巴瘤腿部型：一例报告
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):258. doi: 10.3760/cma.j.issn.0253-2727.2023.03.015.

引用本文的文献

1
Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.MYD88和/或CD79B突变对弥漫性大B细胞淋巴瘤患者中枢神经系统复发的影响。
Br J Haematol. 2025 Jul;207(1):92-100. doi: 10.1111/bjh.20099. Epub 2025 Apr 22.
2
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma.高危弥漫性大B细胞淋巴瘤患者中枢神经系统预防的最新进展。
Exp Hematol Oncol. 2024 Jan 3;13(1):1. doi: 10.1186/s40164-023-00467-2.
3
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.弥漫性大B细胞淋巴瘤基因表达谱分析的生物学及临床意义：作为多层分析方法一部分的靶向BLYM-777联合研究小组方案
Cancers (Basel). 2022 Apr 7;14(8):1857. doi: 10.3390/cancers14081857.
4
mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.突变可确定弥漫性大 B 细胞淋巴瘤的一个分子亚组，该亚组预后不良。
Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.
5
Biology of CNS lymphoma and the potential of novel agents.中枢神经系统淋巴瘤的生物学特性和新型药物的潜力。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):556-564. doi: 10.1182/asheducation-2017.1.556.

本文引用的文献

1
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.原发性睾丸弥漫性大B细胞淋巴瘤中致癌性MYD88和CD79B突变的高发生率。
Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20.
2
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.在免疫特权部位出现的弥漫性大 B 细胞淋巴瘤中，存在高频率的致癌 MYD88 和 CD79B 突变。
Blood Cancer J. 2013 Sep 6;3(9):e139. doi: 10.1038/bcj.2013.28.
3
The genetic basis of diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传学基础。
Curr Opin Hematol. 2013 Jul;20(4):336-44. doi: 10.1097/MOH.0b013e3283623d7f.
4
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
5
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.瓦尔登斯特伦巨球蛋白血症中的 MYD88 L265P 体细胞突变。
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
6
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.原发性中枢神经系统淋巴瘤中 MYD88 和 TBL1XR1 的反复突变。
Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.
7
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.临床上有效的 BTK 抑制剂 PCI-32765 靶向慢性淋巴细胞白血病中 B 细胞受体和趋化因子控制的黏附和迁移。
Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
8
Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.MYD88基因的激活型L265P突变在原发性中枢神经系统淋巴瘤中很常见。
Acta Neuropathol. 2011 Dec;122(6):791-2. doi: 10.1007/s00401-011-0891-2. Epub 2011 Oct 22.
9
Oncogenically active MYD88 mutations in human lymphoma.人类淋巴瘤中致癌性激活的 MYD88 突变。
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
10
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.标准国际预后指数仍然是利妥昔单抗时代侵袭性 CD20+ B 细胞淋巴瘤患者预后的有效预测指标。
J Clin Oncol. 2010 May 10;28(14):2373-80. doi: 10.1200/JCO.2009.26.2493. Epub 2010 Apr 12.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

作者信息

Kersten M J, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin P M, van der Holt B J, Spaargaren M, Pals S T

机构信息

Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.

DOI:10.1038/bcj.2014.87
PMID:25501023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4315893/
Abstract
摘要